These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37014806)

  • 1. Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies.
    Tran KTM; Le TT; Agrahari V; Peet MM; Ouattara LA; Anderson SM; Le-Kim TH; Singh ON; Doncel GF; Nguyen TD
    Mol Pharm; 2023 May; 20(5):2352-2361. PubMed ID: 37014806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension.
    Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Lachau-Durand S; Niemeijer N; Williams P; Haeck C; McCarthy HO; Zehrung D; Donnelly RF
    J Control Release; 2018 Dec; 292():119-129. PubMed ID: 30395897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
    Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
    PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly neutralizing monoclonal antibodies for HIV prevention.
    Miner MD; Corey L; Montefiori D
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
    Flexner C; Owen A; Siccardi M; Swindells S
    Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.
    Hicar MD; Chen X; Kalams SA; Sojar H; Landucci G; Forthal DN; Spearman P; Crowe JE
    Mol Immunol; 2016 Feb; 70():94-103. PubMed ID: 26748387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling.
    Kinvig H; Cottura N; Lloyd A; Frivold C; Mistilis J; Jarrahian C; Siccardi M
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):855-868. PubMed ID: 36178586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.
    Rajoli RKR; Flexner C; Chiong J; Owen A; Donnelly RF; Larrañeta E; Siccardi M
    Eur J Pharm Biopharm; 2019 Nov; 144():101-109. PubMed ID: 31525446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies.
    Vigil A; Frias-Staheli N; Carabeo T; Wittekind M
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
    Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
    mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines.
    Hioe CE; Kumar R; Upadhyay C; Jan M; Fox A; Itri V; Peachman KK; Rao M; Liu L; Lo NC; Tuen M; Jiang X; Kong XP; Zolla-Pazner S
    Front Immunol; 2018; 9():2441. PubMed ID: 30416503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development?
    Parsons MS; Muller S; Kohler H; Grant MD; Bernard NF
    Hum Vaccin Immunother; 2013 Jul; 9(7):1532-8. PubMed ID: 23571168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV Pre-Exposure Prophylaxis.
    Volpe-Zanutto F; Vora LK; Tekko IA; McKenna PE; Permana AD; Sabri AH; Anjani QK; McCarthy HO; Paredes AJ; Donnelly RF
    J Control Release; 2022 Aug; 348():771-785. PubMed ID: 35738464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis.
    Flexner C; Thomas DL; Swindells S
    Curr Opin HIV AIDS; 2019 Jan; 14(1):13-20. PubMed ID: 30394948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
    Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
    J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
    Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
    PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
    Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
    PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly neutralizing antibodies against HIV-1 and concepts for application.
    Gruell H; Schommers P
    Curr Opin Virol; 2022 Jun; 54():101211. PubMed ID: 35306354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Walsh SR; Seaman MS
    Front Immunol; 2021; 12():712122. PubMed ID: 34354713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.